{"doc_id": "32812025", "type of study": "Therapy", "title": "", "abstract": "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.\nNew therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19).\nRepurposing existing pharmaceuticals provides an immediate treatment opportunity.\nWe assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.\nThis was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran.\nPatients were randomly assigned to 400\u2009mg sofosbuvir, 60\u2009mg daclatasvir and 1200\u2009mg ribavirin (intervention group) or to standard care (control group).\nThe primary endpoint of this study was length of hospital stay.\nThis study is registered by IRCT.ir under the ID: IRCT20200328046886N1.\nBetween 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group.\nThe median duration of hospital stay was 6\u2009days in both groups (P\u2009=\u20090.398).\nThe number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P\u2009=\u20090.109).\nThere was no difference in the number of deaths between the groups (0 versus 3, P\u2009=\u20090.234).\nThe cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray's P\u2009=\u20090.033).\nThis randomized trial was too small to make definitive conclusions.\nThere were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates.\nHowever, there was an imbalance in the baseline characteristics between the arms.\nLarger randomized trials should be conducted to investigate this treatment further.\n\u00a9 The Author(s) 2020.\nPublished by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.\nAll rights reserved.\nFor permissions, please email: journals.permissions@oup.com.\n", "Evidence Map": {"Enrollment": [{"term": "hospitalized COVID-19", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 113}, {"term": "moderate disease", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 144}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 105}, {"term": "moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 87}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care : a single-centre , randomized controlled trial .", "Evidence Elements": {"Participant": [{"term": "hospitalized COVID-19", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 113}, {"term": "moderate disease", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 144}], "Intervention": [{"term": "sofosbuvir plus daclatasvir in combination with ribavirin", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 87, "has_chemical": [{"text": "sofosbuvir", "maps_to": "C2976303:sofosbuvir", "start": 0, "end": 10}, {"text": "daclatasvir", "maps_to": "C3252090:daclatasvir", "start": 16, "end": 27}, {"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 48, "end": 57}], "has_relation": "combined_with (C2976303<->C3252090<->C0035525)"}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 159, "end": 172, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Repurposing existing pharmaceuticals provides an immediate treatment opportunity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 105}], "Intervention": [{"term": "sofosbuvir", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 38, "has_chemical": [{"text": "sofosbuvir", "maps_to": "C2976303:sofosbuvir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "daclatasvir with ribavirin", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 69, "has_chemical": [{"text": "daclatasvir", "maps_to": "C3252090:daclatasvir", "start": 0, "end": 11}, {"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 17, "end": 26}], "has_relation": "combined_with (C3252090<->C0035525)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This was a single-centre , randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province , Iran .", "Evidence Elements": {"Participant": [{"term": "moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 87}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned to 400 mg sofosbuvir , 60 mg daclatasvir and 1200 mg ribavirin ( intervention group ) or to standard care ( control group ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "sofosbuvir", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 52, "has_chemical": [{"text": "sofosbuvir", "maps_to": "C2976303:sofosbuvir", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "daclatasvir", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 72, "has_chemical": [{"text": "daclatasvir", "maps_to": "C3252090:daclatasvir", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "ribavirin", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 94, "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "standard", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 132, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary endpoint of this study was length of hospital stay .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "length of hospital stay", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 62}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This study is registered by IRCT.ir under the ID : IRCT20200328046886N1 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Between 20 March 2020 and 8 April 2020 , 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "intervention", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 123, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 151, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The median duration of hospital stay was 6 days in both groups ( P = 0.398 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both groups", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 62, "has_relation": "N/A"}], "Outcome": [{"term": "median duration of hospital stay", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 36}], "Observation": [{"term": "6 days", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 47}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "both groups", "has_relation": "N/A"}, "Observation": "6 days", "Outcome": "median duration of hospital stay", "Count": ""}]}, {"Section": "RESULTS", "Text": "The number of ICU admissions in the sofosbuvir / daclatasvir / ribavirin group was not significantly lower than the control group ( 0 versus 4 , P = 0.109 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ribavirin", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 72, "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "control", "negation": "negated", "UMLS": {}, "start": 116, "end": 123, "has_relation": "N/A"}], "Outcome": [{"term": "number of ICU admissions", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 28}], "Observation": [{"term": "significantly lower", "negation": "negated", "UMLS": {}, "start": 87, "end": 106}, {"term": "0", "negation": "negated", "UMLS": {}, "start": 132, "end": 133}, {"term": "4", "negation": "negated", "UMLS": {}, "start": 141, "end": 142}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "ribavirin", "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "significantly lower", "Outcome": "number of ICU admissions", "Count": ""}, {"Intervention": {"term": "ribavirin", "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}, "Observation": "0", "Outcome": "number of ICU admissions", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "4", "Outcome": "number of ICU admissions", "Count": ""}]}, {"Section": "RESULTS", "Text": "There was no difference in the number of deaths between the groups ( 0 versus 3 , P = 0.234 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the groups", "negation": "negated", "UMLS": {}, "start": 48, "end": 66, "has_relation": "N/A"}], "Outcome": [{"term": "number of deaths", "negation": "negated", "UMLS": {}, "start": 31, "end": 47}], "Observation": [{"term": "difference", "negation": "negated", "UMLS": {}, "start": 13, "end": 23}, {"term": "0", "negation": "negated", "UMLS": {}, "start": 69, "end": 70}, {"term": "3", "negation": "negated", "UMLS": {}, "start": 78, "end": 79}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The cumulative incidence of recovery was higher in the sofosbuvir / daclatasvir / ribavirin arm ( Gray 's P=0.033 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ribavirin", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 91, "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}], "Outcome": [{"term": "cumulative incidence of recovery", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 36}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 47}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "ribavirin", "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}], "Observation": "higher", "Outcome": "cumulative incidence of recovery", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "This randomized trial was too small to make definitive conclusions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "There were trends in favour of the sofosbuvir / daclatasvir / ribavirin arm for recovery and lower death rates .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ribavirin", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 71, "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}], "Outcome": [{"term": "recovery", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 88}, {"term": "death rates", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 110}], "Observation": [{"term": "trends", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 17}, {"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 98}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "ribavirin", "has_chemical": [{"text": "ribavirin", "maps_to": "C0035525:ribavirin", "start": 0, "end": 9}], "has_relation": "N/A"}, "Observation": "trends", "Outcome": "recovery", "Count": ""}, {"Intervention": [], "Observation": "lower", "Outcome": "", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "However , there was an imbalance in the baseline characteristics between the arms .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 76, "has_relation": "N/A"}], "Outcome": [{"term": "baseline characteristics", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 64}], "Observation": [{"term": "imbalance", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 32}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Larger randomized trials should be conducted to investigate this treatment further .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 The Author (s ) 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "For permissions , please email : journals . permissions @ oup.com .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}